NCT05511844 - Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 3, 2022

Primary Completion Date

June 2, 2025

Study Completion Date

June 2, 2025

Conditions

HER2-positive Breast CancerHER-2 Protein OverexpressionHER-2 Gene AmplificationHER2 Gene Mutation

Interventions

DRUG

ORM-5029

Intravenous infusion

Trial Locations (11)

Memorial Sloan Kettering Cancer Center, New York

Weill Cornell Medicine-New York, New York

NEXT Oncology - Virginia Cancer Specialists, Fairfax

Sarah Cannon Research Institute at Tennessee Oncology, Nashville

University of Alabama Birmingham, Birmingham

Washington University, St Louis

MD Anderson Cancer Center, Houston

NEXT Oncology, San Antonio

University of California - Los Angeles, Los Angeles

Fred Hutchinson Cancer Center, Seattle

Dana Farber Cancer Institute, Boston